North America Ophthalmology Drugs & Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America Ophthalmology Drugs & Devices Market: by Type (Drugs, Devices), Application (Cataract, Glaucoma, Refractive Errors, Age-related Macular Degeneration, Others), Distribution Channels (Hospitals, Clinics, Retail Pharmacies, Online, Others), Technology (LASIK, Photocoagulation, Vitrectomy, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20487 | Author: Lily
North America Ophthalmology Drugs & Devices Market Outlook 2025-2035
The North America Ophthalmology Drugs & Devices Market encompasses a diverse set of products and services dedicated to the diagnosis, treatment, and management of eye disorders. This market includes drugs for conditions like glaucoma, cataract, and age-related macular degeneration, as well as medical devices such as implants, surgical instruments, diagnostics, and consumables. The sector is witnessing sustained growth due to rising geriatric population, spike in diabetes-linked eye diseases, and fast adoption of advanced eye-care technologies. Collaborations between pharmaceutical giants and tech companies are also reshaping patient pathways, driving up adoption of innovations such as minimally invasive glaucoma surgery (MIGS) and digital ophthalmic diagnostics. Increased direct-to-consumer offerings, higher healthcare access, and growing awareness are further fueling the market, making ophthalmology a dynamic healthcare subdivision in North America.
Latest Market Dynamics
Key Drivers
Aging population leading to increased prevalence of ophthalmic diseases. Companies such as
are expanding product portfolios to meet rising cataract and age-related macular degeneration cases.
Adoption of advanced surgical technologies like LASIK and MIGS. Recent investments by Carl Zeiss Meditec in digital surgery platforms highlight a strong push for technology-driven procedures.
Key Trends
Growth in tele-ophthalmology and digital diagnostics for remote patient management, with Topcon Corporation developing AI-powered diagnostic devices.
Increased mergers and acquisitions in the sector, as seen with Bausch + Lomb acquiring biotech startups for advanced retinal solutions.
Key Opportunities
Expansion of minimally invasive surgical devices, such as new MIGS devices developed by Glaukos, to cater for unmet needs in glaucoma management.
Surge in demand for combination therapies for diabetic retinopathy, driven by developments from companies like Novartis.
Key Challenges
Stringent regulatory requirements slowing product launches. For example, FDA's new safety protocols have delayed several device approvals.
Competitive pricing pressure from generics and biosimilars, impacting market share for large brands like Allergan (AbbVie).
Key Restraints
High cost of advanced ophthalmic devices and procedures limiting access for underinsured populations, as noted by Santen Pharmaceutical’s outreach programs.
Limited reimbursement policies for newer technologies in both U.S. and Canada, discussed recently in industry whitepapers.
In 2025, the North American ophthalmology drugs & devices market is segmented predominantly between drugs and devices, with devices commanding the larger share due to significant investments in diagnostic and surgical tools. Devices account for 42% of the market, reflecting accelerated adoption of innovative technologies across clinics and hospitals. Drugs, including anti-glaucoma and anti-VEGF therapies, represent 35% of the market, underpinned by continuous drug approvals and extended indications for existing therapies. Diagnostic devices—comprising retinal imaging and tonometry—take a 15% share, while surgical instruments and consumables account for the remaining 8%. The surge in device usage is linked to heightened investment by established vendors and increasing procedural volumes, as aging demographics fuel the demand for cataract and refractive surgeries. The competitive landscape remains robust, motivating players to introduce new features and enhance clinical outcomes.
By application, cataract treatments hold the largest share of the North American market at 34%, driven primarily by the aging baby boomer population and the prevalent use of phacoemulsification technology. Glaucoma therapies follow at 26% as heightened screening initiatives and minimally invasive therapies (MIGS) gain traction. Treatments for refractive errors capture a 21% market share, catalyzed by increased consumer interest in LASIK and corrective lens implants. The remaining 19% covers age-related macular degeneration, diabetic retinopathy, and other ophthalmic conditions. Rapid uptake of innovative approaches, such as anti-VEGF injections and digital retina imaging, has contributed to robust growth in all segments. This diversified application landscape affords resilience and maintains demand, even as healthcare delivery models evolve towards telemedicine and ambulatory care.
Market revenue for the North America Ophthalmology Drugs & Devices sector is projected to experience consistent growth from 2020 through 2035. In 2021, revenue stood at 13,800 million, rising to 18,900 million by 2025 on the strength of growing demand for advanced treatments and technology adoption. The market is further forecasted to expand, reaching 27,400 million by 2030 and surpassing 37,200 million in 2035. This positive trajectory is fueled by advances in surgical devices, targeted therapies, and demographic shifts such as an increasingly aging population. The upward revenue trend underlines the sector's robust ecosystem and continued investments in next-generation diagnostic and treatment solutions.
The North American ophthalmology drugs & devices market has exhibited steady year-over-year (YoY) growth, with 2021 seeing an increase of 6.8% over the previous year. Growth accelerates to 7.5% in 2025, driven by rising demand for cataract and glaucoma treatments as well as robust device innovations. By 2030, the YoY growth moderates to 6.4% as the market matures but remains strong owing to rising adoption of digital and tele-ophthalmology tools. The projected YoY growth for 2035 stands at 5.6%, indicating continued resilience and expansion despite evolving reimbursement climates and competitive pressures. This consistent trajectory reinforces the industry's stability and attractiveness for investment.
In 2025, the United States dominates the North America ophthalmology drugs & devices market, commanding 76% of total regional revenue. Canada contributes 14%, reflecting robust investment in healthcare infrastructure and a growing elderly demographic. Mexico accounts for 10%, driven by increasing private sector collaborations and enhanced access to vision health services. The pronounced US share underscores ongoing R&D investment and rapid commercialization of next-gen ophthalmic solutions. Canadian and Mexican markets, though smaller, present high growth potential due to increasing disease awareness, public health policies, and improved reimbursement structures. Regional diversification is expected to remain a key focus area for leading market players.
Alcon leads the North America ophthalmology market with a 19% share in 2025, followed by Johnson & Johnson Vision at 16% and Bausch + Lomb at 14%. These top players maintain robust portfolios across drugs, devices, and surgical instruments. Novartis and Allergan (AbbVie) together account for 19%, leveraging strong pipelines and life-cycle management strategies. The remaining 32% is distributed among innovative entrants like Carl Zeiss Meditec, STAAR Surgical, Topcon, and regionally focused players. The competitive landscape is characterized by ongoing R&D, aggressive product launches, and strategic alliances aimed at comprehensive disease management and digital transformation.
Hospitals represent the largest buyer segment for ophthalmology drugs & devices in North America, accounting for 39% in 2025. Clinics hold 29%, reflecting the continued expansion of specialized outpatient care. Retail pharmacies and optical stores combined represent 18%, as more consumers seek vision healthcare beyond traditional hospital settings. Online channels and others account for the remaining 14%, boosted by growing digital health adoption and telemedicine services. This distribution underscores the sector’s shift toward decentralized, patient-centric care models, while maintaining strong institutional demand.
June 2024: Alcon announced the launch of a new intraocular lens platform in the US, aiming to enhance post-cataract surgical vision quality.
July 2024: Johnson & Johnson Vision received FDA clearance for its next-gen phacoemulsification device, optimizing cataract surgery safety and efficiency.
August 2024: Bausch + Lomb completed the acquisition of a digital retina imaging startup, strengthening its diagnostics solutions portfolio.
August 2024: Glaukos launched an advanced minimally invasive glaucoma surgery (MIGS) system, approved for expanded use in Canada.
September 2024: Novartis introduced a novel anti-VEGF therapy for diabetic retinopathy, gaining rapid adoption across North American clinics.
Frequently Asked Questions
About the Author
Lily
Senior Market Research Analyst
Lily is a Senior Market Research Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Lily brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Lily has helped organizations translate data into actionable growth strategies.
